Overview of Price Target Increase#

BTIG has raised its price target for Oruka Therapeutics (NASDAQ:ORKA) from $78 to $151 while keeping a Buy rating on the stock. Currently, the stock is trading at $83.41, with a market capitalization of $4.18 billion. This reflects an impressive 584% return over the past year. However, some analysts believe the stock may be overvalued at this price, suggesting that a more conservative target aligns better with fundamental metrics.

Trial Results for ORKA-001#

The increase in price target follows the release of 16-week results from the EVERLAST-A trial for ORKA-001, a treatment being developed for psoriasis. BTIG noted that these results set a new standard for effectiveness within the IL-23 class of psoriasis treatments. Additionally, updates from the Phase 1 PK/PD trial indicated that ORKA-001 could potentially allow for once-a-year maintenance dosing, which would be a first for monoclonal antibodies in any treatment area.

High Probability of Success#

BTIG has raised its probability of success for ORKA-001 in treating psoriasis to 90%. They also increased the expected market penetration for the drug from 21% to 25% and adjusted their discount rate from 15% to 13%. Upcoming data from the 28-week EVERLAST-A trial is expected in the latter half of 2026, while results from the Phase 2b EVERLAST-B trial are anticipated in 2027.

Positive Interim Results#

In related news, Oruka Therapeutics announced favorable interim results from its EVERLAST-A Phase 2a trial involving 84 patients with moderate-to-severe plaque psoriasis. The trial successfully met its primary endpoint, with 63.5% of participants achieving complete skin clearance. The 16-week data showed a 64% PASI100 rate, surpassing expectations set by Stifel, which predicted rates of 40-50% in line with another treatment, Skyrizi. Following these results, Stifel raised its price target for Oruka Therapeutics to $150 and increased the probability of success for ORKA-001 to 75%. TD Cowen also reiterated a Buy rating as the company prepares for more clinical trial results.